• Home Dutch
  •  EN 
  • Employee login

The use of a multiple parameter response efficacy score to predict the effect of a drug on hard renal and cardiovascular

Print 

Title:   The use of a multiple parameter response efficacy score to predict the effect of a drug on hard renal and cardiovascular outcomes
Investigator:  Bauke Schievink 
Supervisor:  Hiddo Lambers Heerspink 
Promotor:  Dick de Zeeuw 
Summary:   Currently drugs are registered on the basis of one marker of efficacy (e.g. blood pressure for renoprotection) and on the basis of being a safe drug. However, drugs have multiple effects that contribute to its effect on hard renal outcome. For example, AII-antagonists do not only lower blood pressure but also lower albuminuria and increase serum potassium. The latter may blunt the ultimate effect on hard renal outcome. Thus the composite short-term effect of a drug on all different markers should be measured and evaluated to ascertain the drugs efficacy. In this project we validate a so called multiple parameter risk efficacy(PRE) score that combines short-term changes in different biomarkers to predict the effect of a drug on long-term renal and cardiovascular outcome. 
Financing: Escher value creation project 
Start:  1-06-2008 
End:  1-09-2015 

Projects
The use of a multiple parameter response efficacy score to predict the effect of a drug on hard renal and cardiovascular
Diabetes Mellitus Treatment for Renal Insufficiency Consortium (DIAMETRIC) database 
System biology approach for discovery of biomarkers of renal disease progressioni in diabetes (SysKid)
PROVALID – prospective multinational cohort study in patients with type 2 diabetes treated in primary care
Vitamin-D deficiency as a risk marker for renal and CV complications in the general population
A novel approach of personalized medicine: considering multiple effects of a single drug
Optimal hard endpoints in clinical trials of renal disease progression
Albuminuria as surrogate endpoint in clinical trials
Individual therapy response to a sodium-glucose transport inhibitor
Involving patients in the assessment and evaluation of medication treatment
Groningen Initiative to Analyse Type-2 diabetes Treatment ( GIANTT )
The role of medication adherence in predicting treatment response and estimating cost-effectiveness of statin treatment
Pharmacogenetics and response to treatment of oral antidiabetics
Quality of prescribing: patient specific indicators that predict better outcomes in diabetes patients
Quality assessment of pharmacotherapy in patients with chronic kidney disease
Cost effectiveness of ACEi and ARBs on renal failure in diabetes patients
Drug information and risk communication in Africa
Regulatory Science Projects